The effects of 2'-o-methoxyethyl oligonucleotides on renal function in humans

Nucleic Acid Therapeutics

Volumn 28, Issue 1, 2018, Pages 10-22

  Crooke, Stanley T ^a   Baker, Brenda F ^a   Pham, Nguyen C ^a   Hughes, Steven G ^a   Kwoh, T Jesse ^a   Cai, Danlin ^a   Tsimikas, Sotirios ^a   Geary, Richard S ^a   Bhanot, Sanjay ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

antisense; clinical trials; humans; kidney; oligonucleotide; safety

Indexed keywords

2' O METHOXYETHYL OLIGONUCLEOTIDE; ALBUMIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANALGESIC AGENT; ANTICOAGULANT AGENT; ANTIFUNGAL AGENT; ANTIGOUT AGENT; ANTIHISTAMINIC AGENT; ANTIINFLAMMATORY AGENT; ANTIMYCOBACTERIAL AGENT; ANTIPROTOZOAL AGENT; ANTIRHEUMATIC AGENT; ANTISENSE OLIGONUCLEOTIDE; ANTIVIRUS AGENT; BETA LACTAM ANTIBIOTIC; BICARBONATE; BISPHOSPHONIC ACID DERIVATIVE; CHLORIDE; CIPROFLOXACIN; CREATININE; DIURETIC AGENT; ELECTROLYTE; IMMUNOSUPPRESSIVE AGENT; OXICAM DERIVATIVE; POTASSIUM; SODIUM; SULFONAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA; VOLANESORSEN; APOLIPOPROTEIN; BLOOD CLOTTING FACTOR 11; GLUCOCORTICOID RECEPTOR; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE KINASE;

ABNORMAL VALUE; ACUTE KIDNEY FAILURE; ADULT; ALBUMIN BLOOD LEVEL; ANTISENSE THERAPY; ARTICLE; AUTOIMMUNE DISEASE; BICARBONATE BLOOD LEVEL; CHLORIDE BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC PATIENT; DOSE RESPONSE; DRUG SAFETY; ELECTROLYTE BLOOD LEVEL; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HUMAN; HYPERLIPIDEMIA; INFLAMMATION; KIDNEY FUNCTION; KIDNEY FUNCTION TEST; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEPHROTOXICITY; OBESITY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SODIUM BLOOD LEVEL; THROMBOSIS; TREATMENT DURATION; UREA NITROGEN BLOOD LEVEL; ANTAGONISTS AND INHIBITORS; BLOOD; GENETICS; GLOMERULUS FILTRATION RATE; META ANALYSIS; METABOLISM; PATHOPHYSIOLOGY; PATIENT SAFETY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADULT; APOLIPOPROTEINS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; CREATININE; DIABETES MELLITUS; FACTOR XI; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; OBESITY; OLIGONUCLEOTIDES, ANTISENSE; PATIENT SAFETY; PROTEIN TYROSINE PHOSPHATASES, NON-RECEPTOR; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GLUCOCORTICOID; THROMBOSIS;

EID: 85041296080     PISSN: 21593337     EISSN: 21593345     Source Type: Journal    
DOI: 10.1089/nat.2017.0693     Document Type: Article

References (25)

1. Crooke ST, ed. (2008). Antisense Drug Technology Principles, Strategies, and Applications, 2nd ed. CRC Press, New York.
2. Bennett CF. (2008). Pharmacological properties of 2'-Omethoxyethyl-modified oligonucleotides. In: Antisense Drug Technology, Principles, Strategies and Applications, 2nd ed. Crooke ST, ed. CRC Press, New York, pp 273-303.
3. Levin AA, RZ Yu and RS Geary. (2008). Basic principles of the pharmacokinetics of antisense oligonucleotide drugs. In: Antisense Drug Technology, Principles, Strategies and Applications, 2nd ed. ST Crooke, ed. CRC Press, New York, pp 183-215.
4. Geary RS, RS Yu, A Siwkowski and AA Levin. (2008). Pharmacokinetic/pharmacodynamic properties of phosphorothioate 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides in animals and man. In: Antisense Drug Technology, Principles, Strategies and Applications, 2nd ed. ST Crooke, ed. CRC Press, New York, pp 305-326.
5. Henry SP, TW Kim, K Kramer-Strickland, TA Zanardi, RA Fey and AA Levin. (2008). Toxicological properties of 2'-O-methoxyethyl chimeric antisense inhibitors in animals and man. In: Antisense Drug Technology, Principles, Strategies and Applications, 2nd ed. ST Crooke, ed. CRC Press, New York, pp 327-363.
6. Bennett CF, BF Baker, N Pham, E Swayze and RS Geary. (2017). Pharmacology of antisense drugs. Annu Rev Pharmacol Toxicol 57:81-105.
7. Crooke ST, BF Baker, TJ Kwoh, W Cheng, DJ Schulz, S Xia, N Salgado, H-H Bui, CE Hart, et al. (2016). Integrated safety assessment of 2'-O-methoxyethyl chimeric antisense oligonucleotides in nonhuman primates and healthy human volunteers. Mol Ther 24:1771-1782.
8. Crooke ST, BF Baker, JL Witztum, TJ Kwoh, NC Pham, N Salgado, BW McEvoy, W Cheng, SG Hughes, S Bhanot and RS Geary. (2017). The effects of 2'-O-methoxyethyl containing antisense oligonucleotides on platelets in human clinical trials. Nucleic Acid Ther 27:121-129.
9. Zanardi TA, SC Han, EJ Jeong, S Rime, RZ Yu, K Chakravarty and SP Henry. (2012). Pharmacodynamics and subchronic toxicity in mice and monkeys of ISIS 388626, a second-generation antisense oligonucleotide that targets human sodium glucose cotransporter 2. J Pharmacol Exp Ther 343:489-496.
10. van Meer L, M Moerland, M van Dongen, B Goulouze, M de Kam, E Klaassen, A Cohen and J Burggraaf. (2016). Renal effects of antisense-mediated inhibition of SGLT2. J Pharmacol Exp Ther 359:280-289.
11. van Meer L, M van Dongen, M Moerland, M de Kam, A Cohen and J Burggraaf. (2017). Novel SGLT2 inhibitor: First-in-man studies of antisense compound is associated with unexpected renal effects. Pharmacol Res Perspect 5: E00292.
12. Ionis Pharmaceuticals, Inc. press release on phase 3 inotersen topline results. http://ir.ionispharma.com/phoenix .zhtml?c=222170&p=irol-newsArticle&ID=2272828 Accessed on August 18, 2017.
13. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute. (2010). Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 ( June 2010). https://evs.nci.nih.gov/ftp1/ CTCAE/CTCAE-4.03-2010-06-14-QuickReference-8.5 11 .pdf. Accessed on August 18, 2017.
14. Levey AS, JP Bosch, JB Lewis, T Greene, N Rogers and D Roth. (1999). A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 130:461-470.
15. Naughton CA. (2008). Drug-induced nephrotoxicity. Am Fam Physician 78:743-750.
16. Perazella MA and RL Luciano. (2015). Review of select causes of drug-induced AKI. Expert Rev Clin Pharmacol 8: 367-371.
17. Fried LF, N Emanuele, JH Zhang, M Brophy, TA Conner, W Duckworth, DJ Leehey, PA McCullough, T O'Connor, et al. (2013). Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369:1892-1903.
18. Beldhuis IE, KW Streng, JM Ter Maaten, AA Voors, P van der Meer, P Rossignol, JJ McMurray and K Damman. (2017). Renin-angiotensin system inhibition, worsening renal function, and outcome in heart failure patients with reduced and preserved ejection fraction: A meta-analysis of published study data. Circ Heart Fail 10:pii: E003588.
19. Lobato L and A Rocha. (2012). Transthyretin amyloidosis in the kidney. Clin J Am Soc Nephrol 7:1337-1346.
20. Stevens LA, J Coresh, HI Feldman, T Greene, JP Lash, RG Nelson, M Rahman, AE Deysher, YL Zhang, CH Schmid and AS Levey. (2007). Evaluation of the modification of diet in renal disease study equation in a large diverse population. J Am Soc Nephrol 18:2749-2757.
21. Tsimikas S, NJ Viney, SG Hughes, W Singleton, MJ Graham, BF Baker, JL Burkey, Q Yang, SM Marcovina, et al. (2015). Antisense therapy targeting apolipoprotein(a): A randomised, double-blind, placebo-controlled phase 1 study. Lancet 386:1472-1483.
22. Viney NJ, JC van Capelleveen, RS Geary, S Xia, JA Tami, RZ Yu, SM Marcovina, SG Hughes, MJ Graham, et al. (2016). Antisense oligonucleotides targeting apolipoprotein( a) in people with raised lipoprotein(a): Two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet 388:2239-2253.
23. Yu RZ, R Gunawan, N Post, T Zanardi, S Hall, J Burkey, TW Kim, MJ Graham, TP Prakash, et al. (2016). Disposition and pharmacokinetics of a GalNAc3-conjugated antisense oligonucleotide targeting human lipoprotein (a) in monkeys. Nucleic Acid Ther 26:372-380.
24. Yu RZ, MJ Graham, N Post, S Riney, T Zanardi, S Hall, J Burkey, CS Shemesh, TP Prakash, et al. (2016). Disposition and pharmacology of a GalNAc3-conjugated ASO targeting human lipoprotein (a) in mice. Mol Ther Nucleic Acids 5:e317.
25. Graham MJ, RG Lee, TA Brandt, LJ Tai, W Fu, R Peralta, R Yu, E Hurh, E Paz, et al. (2017). Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides. N Engl J Med 377:222-232.